RATINGS CHANGES

Akorn (AKRX - Get Report) was downgraded to underperform from buy at Bank of America/Merrill Lynch. $22 price target. The company is facing potential risks on several fronts, analysts said. 

Biogen (BIIB - Get Report) was upgraded to overweight from neutral at Piper Jaffray. $335 price target. The valuation is reasonable, given opportunities in Alzheimer's and SMA, Piper said. 

BioMarin (BMRN - Get Report) was downgraded to neutral from overweight at Piper Jaffray. $84 price target. The valuation is less attractive, given limited visibility, Piper said. 

Ford (F - Get Report) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: F.

GoPro (GPRO - Get Report) was downgraded to underperform from buy at Bank of America/Merrill Lynch. $10 price target. Earnings estimates were also cut, given the company's new guidance, analysts said. 

Impax (IPXL) was downgraded to underperform from neutral at Bank of America/Merrill Lynch. $19 price target. The company may miss 2016 targets, analysts said. 

ITT (ITT - Get Report) was upgraded to overweight from sector weight at Keybanc. The valuation is more attractive, based on a $40 price target, Keybanc said. 

L Brands (LB - Get Report) was downgraded to underperform at Jefferies. $50 price target. The company is facing increased competition and earnings are now expected to decline in 2018, Jefferies said. 

Parker Hannifin (PH - Get Report) was upgraded to overweight at Morgan Stanley. $139 price target. The company is reasonably valued and can delivery above-average earnings growth in the coming quarters, Morgan Stanley said. 

Premier (PINC - Get Report) was downgraded underperform from buy at Bank of America/Merrill Lynch. $30 price target. The specialty pharma business is posing greater risk, analysts said. 

Take-Two Interactive Software (TTWO - Get Report) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: TTWO.

Time Warner (TWX) was upgraded to outperform from neutral at Credit Suisse. $107.50 price target. Regulatory pessimism appears overdone, Credit Suisse said. 

Xerox (XRX - Get Report) was downgraded to underweight at Morgan Stanley. $9.50 price target. BPO and document technology performance remains weak, Morgan Stanley said. 

This article was written by a staff member of TheStreet.